A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
<h4>Background</h4>The E7 protein of the Human Papillomavirus (HPV) type 16, being involved in malignant cellular transformation, represents a key antigen for developing therapeutic vaccines against HPV-related lesions and cancers. Recombinant production of this vaccine antigen in an act...
Guardado en:
Autores principales: | Olivia C Demurtas, Silvia Massa, Paola Ferrante, Aldo Venuti, Rosella Franconi, Giovanni Giuliano |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0963fa34853949e3bb62bab97b1d3536 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Maturation of the Human Papillomavirus 16 Capsid
por: Giovanni Cardone, et al.
Publicado: (2014) -
Human papillomavirus in skin tags: a case series
por: Caterina Dianzani, et al.
Publicado: (2018) -
Engineering the chloroplast targeted malarial vaccine antigens in Chlamydomonas starch granules.
por: David Dauvillée, et al.
Publicado: (2010) -
Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody
por: Shiwen Peng, et al.
Publicado: (2021) -
Human Papillomavirus 16 E6 and E7 Synergistically Repress Innate Immune Gene Transcription
por: Claire D. James, et al.
Publicado: (2020)